Who are liposomal amphotericin B + miltefosine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Vivjoa, Brexafemme, Brexafemme, Cresemba, Jublia, Luzu.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/liposomal-amphotericin-b-miltefosine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

liposomal amphotericin B + miltefosine — Competitive Intelligence Brief

liposomal amphotericin B + miltefosine (liposomal amphotericin B + miltefosine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antifungal. Area: Infectious Diseases.

phase 3 Antifungal Ergosterol, Sphingosine N-acyltransferase Infectious Diseases Small molecule Live · refreshed every 30 min

Target snapshot

liposomal amphotericin B + miltefosine (liposomal amphotericin B + miltefosine) — Drugs for Neglected Diseases. Liposomal amphotericin B targets fungal cell membranes, while miltefosine targets fungal cell membranes and inhibits sphingosine N-acyltransferase.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
liposomal amphotericin B + miltefosine TARGET	liposomal amphotericin B + miltefosine	Drugs for Neglected Diseases	phase 3	Antifungal	Ergosterol, Sphingosine N-acyltransferase
Vivjoa	OTESECONAZOLE	Mycovia Pharms	marketed	Azole Antifungal [EPC]	Cytochrome P450 3A4	2022-01-01
Brexafemme	IBREXAFUNGERP CITRATE	GSK	marketed	Triterpenoid Antifungal		2021-01-01
Brexafemme	IBREXAFUNGERP	GSK	marketed	Triterpenoid Antifungal		2021-01-01
Cresemba	ISAVUCONAZONIUM	Astellas Pharma	marketed	Azole Antifungal	ATP-binding cassette sub-family G member 2	2015-01-01
Jublia	EFINACONAZOLE	Bausch Health	marketed	Azole Antifungal [EPC]		2014-01-01
Luzu	LULICONAZOLE	Bausch Health	marketed	Azole Antifungal [EPC]		2013-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antifungal class)

Cidara Therapeutics Inc. · 1 drug in this class
Drugs for Neglected Diseases · 1 drug in this class
Fernanda P Silveira, MD, MS · 1 drug in this class
LI YAN · 1 drug in this class
Novartis · 1 drug in this class
Polichem S.A. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). liposomal amphotericin B + miltefosine — Competitive Intelligence Brief. https://druglandscape.com/ci/liposomal-amphotericin-b-miltefosine. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab